Zentalis Pharmaceuticals, Inc. Common Stock
Market Cap
280M
Short interest (May 15)
6.9%
Net Short (Jun 03 ): 0.2%
Borrow Fee
0.31%
↓ 5.0%
Available Shares
2M
↓ 13.0%
Price Chart
Company Overview
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.